Literature DB >> 31131492

Quality of life after external beam radiotherapy for localized prostate cancer: Comparison with other modalities.

Katsumasa Nakamura1, Kenta Konishi1, Tetsuya Komatsu1, Ryo Ishiba1.   

Abstract

In external beam radiotherapy for localized prostate cancer, acute toxicities are typically transient and mild. These symptoms will disappear within 4-8 weeks after external beam radiotherapy. Some patients might suffer from proctitis with bloody stools as late rectal toxicity. Therefore, it has been shown that external beam radiotherapy has a more pronounced negative impact on bowel function compared with other treatment modalities. However, the recent development of modern beam delivery techniques, including intensity-modulated radiotherapy, allows us not only to deliver higher doses to the prostate, but also to decrease the doses to the critical organs, resulting in the maintenance of patients' quality of life within satisfactory levels. Patients' quality of life after external beam radiotherapy is also strongly related to the total dose, fractionation regimens, dose parameters of the critical organs and treatment plan quality, with a trade-off between the radicality of external beam radiotherapy and potentially increased toxicity. Radiation oncologists should choose treatment parameters carefully to achieve a reasonable balance between a good oncological outcome and the patient's quality of life.
© 2019 The Japanese Urological Association.

Entities:  

Keywords:  external beam radiotherapy; proctitis; prostate cancer; quality of life; rectal bleeding

Year:  2019        PMID: 31131492     DOI: 10.1111/iju.14026

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  4 in total

Review 1.  Narrative review of urinary glycan biomarkers in prostate cancer.

Authors:  Shingo Hatakeyama; Tohru Yoneyama; Yuki Tobisawa; Hayato Yamamoto; Chikara Ohyama
Journal:  Transl Androl Urol       Date:  2021-04

Review 2.  A Ten-year-long Update on Radiation Proctitis Among Prostate Cancer Patients Treated With Curative External Beam Radiotherapy.

Authors:  Gianluca Ferini; Stefano Pergolizzi
Journal:  In Vivo       Date:  2021-04-28       Impact factor: 2.406

3.  Treating the primary in low burden metastatic prostate cancer: Where do we stand?

Authors:  Hua-Chun Luo; Zhi-Chao Fu; Xin-Peng Wang; Lv-Juan Cai; Feng-Mei Wang; Qin Yin; Guishan Lin; Zhong-Hua Chen; Shao-Guang Liao
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.817

4.  Neoadjuvant radiation above NCCN guidelines for rectal cancer is associated with age under 50 and early clinical stage.

Authors:  Jonathan T Bliggenstorfer; Katherine Bingmer; Asya Ofshteyn; Sharon L Stein; Ronald Charles; Emily Steinhagen
Journal:  Surg Endosc       Date:  2021-06-10       Impact factor: 4.584

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.